Helen Torley, PRESIDENT AND CEO at HALOZYME THERAPEUTICS, INC. (HALO), sold 30,000 shares at $53.31 ($1.6M) on 2024-10-09, disclosed to the SEC on 2024-10-09.
Scheduled sale ($1.6M) by PRESIDENT AND CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $53.94 | 9,100 | $491K | 30.8% |
| 2 | $54.57 | 900 | $49K | 3.1% |
| 3 | $51.85 | 5,981 | $310K | 19.5% |
| 4 | $51.85 | 5,981 | $310K | 19.5% |
| 5 | $53.31 | 1,615 | $86K | 5.4% |
| 6 | $53.31 | 1,615 |
| $86K |
| 5.4% |
| 7 | $53.91 | 2,404 | $130K | 8.1% |
| 8 | $53.91 | 2,404 | $130K | 8.1% |
| Total | $53.05 avg | 30,000 | $1.6M | 100% |
| Filing → |
| HALO | SELL | 2026-08-19 | $6.3M | — | Filing → |
| HALO | SELL | 2026-07-09 | $153K | — | Filing → |
| HALO | SELL | 2026-06-03 | $3.4M | — | Filing → |